| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 701 |
| 1 | NIVOLUMAB | 319 |
| 2 | CARBOPLATIN | 286 |
| 3 | IPILIMUMAB | 210 |
| 4 | PACLITAXEL | 183 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 177 |
| 6 | LENVATINIB | 98 |
| 7 | PEMETREXED DISODIUM | 78 |
| 8 | CISPLATIN | 69 |
| 9 | CYCLOPHOSPHAMIDE | 69 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PEMBROLIZUMAB | 701 | 0.0065 |
| 1 | IPILIMUMAB | 210 | 0.0048 |
| 2 | DOSTARLIMAB | 11 | 0.0044 |
| 3 | FOSNETUPITANT AND PALONOSETRON | 5 | 0.0042 |
| 4 | NETUPITANT AND PALONOSETRON | 5 | 0.0042 |
| 5 | NIVOLUMAB | 319 | 0.0033 |
| 6 | LENVATINIB | 98 | 0.0029 |
| 7 | TREMELIMUMAB | 11 | 0.0025 |
| 8 | CARBOPLATIN | 286 | 0.0022 |
| 9 | DURVALUMAB | 45 | 0.0021 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1044 |
| 1 | Platinum-based Drug [EPC] | 357 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 221 |
| 3 | Microtubule Inhibitor [EPC] | 186 |
| 4 | Kinase Inhibitor [EPC] | 121 |
| 5 | Alkylating Drug [EPC] | 70 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 59 |
| 7 | Programmed Death Ligand-1 Blocker [EPC] | 46 |
| 8 | Corticosteroid [EPC] | 44 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 39 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1044 | 0.0106 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 221 | 0.0046 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 46 | 0.0021 |
| 3 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 18 | 0.0021 |
| 4 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 5 | Platinum-based Drug [EPC] | 357 | 0.0013 |
| 6 | Microtubule Inhibitor [EPC] | 186 | 0.0011 |
| 7 | Prostacycline [EPC] | 1 | 0.0011 |
| 8 | Endoglycosidase [EPC] | 1 | 0.0005 |
| 9 | Chloride Channel Activator [EPC] | 3 | 0.0003 |